Galectin Therapeutics Inc
GALT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001133416
In the last 90 days, Galectin Therapeutics Inc insiders filed 0 open-market purchases and 1 sale; 98 institutions reported holding it in 13F filings for Q2 2026, worth $72.2M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Galectin Therapeutics Inc changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 59 | 73 | +14 |
| Shares | 7.62M | 9.52M | +1.90M (+24.9%) |
| Value | $18.2M | $21.6M | +$3.40M (+18.7%) |
New holders (23)
Institutions that held Galectin Therapeutics Inc at the end of Q2 2024 but not at the end of Q1 2024.
Sold out (9)
Institutions that held Galectin Therapeutics Inc at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Qube Research & Technologies Ltd | 69,045 | $165.0K |
| Jane Street Group, LLC | 36,785 | $87.9K |
| Creative Planning | 24,214 | $57.9K |
| Wedbush Securities Inc | 15,498 | $37.0K |
| Shepherd Kaplan Krochuk, LLC | 12,000 | $28.7K |
| Y-Intercept (Hong Kong) Ltd | 11,140 | $26.6K |
| CoreCap Advisors, LLC | 7,695 | $18.4K |
| Meeder Asset Management Inc | 3,817 | $9.12K |
| Group One Trading, L.P. | 542 | $1.29K |